Nancy J. Sullivan, ScD
Edward Avedisian Professor
Boston University




Dr. Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.

Dr. Sullivan completed a doctor of science from Harvard T.H. Chan School of Public Health in 1997. She conducted a dissertation in the laboratory of Joseph Sodroski, where her work demonstrated that primary HIV isolates exhibit resistance to antibody neutralization due to occlusion of the coreceptor binding site on gp120. Following her work on HIV, Sullivan pursued postdoctoral training under the guidance of Gary Nabel, studying the mechanisms of Ebola virus pathogenesis and immune protection.

Dr. Sullivan is a cell biologist. She is a tenured senior investigator and chief of the biodefense research section at the Vaccine Research Center.

Dr. Sullivan’s research is on the immunologic correlates and mechanisms of protection against infection by hemorrhagic fever viruses including Ebola virus. Her work on filovirus immunology and vaccine development is widely considered as one of the very best in the field despite the difficulties of conducting research under highly specialized BSL-4 containment conditions. Dr. Sullivan’s innovative and specialized work on filovirus immunology is recognized worldwide and has consistently been the source of novel observations that have contributed to critical advancements in the field.

Dr. Sullivan’s long-term commitment to Ebola research has resulted in discovery of both vaccines and therapies. By using a novel gene-based prime boost vaccine, Dr. Sullivan and her team were the first to demonstrate vaccine protection against Ebola infection in primates. This was followed by her discovery of a single shot vaccine that provided more immediate protection, making it a very practical vaccine that could be used in the face of an acute Ebola epidemic. As a result, this vaccination schedule is now standard in the field of Ebola vaccine research, where one of the lead Ebola vaccine candidates, ChAd3-EBOV, has been advanced to Phase I/II and III human clinical trials. More recently, Dr. Sullivan and her team discovered a potently protective monoclonal antibody, mAb114, from a human Ebola survivor that completely rescues Ebola-infected primates, even when given as a monotherapy several days after their Ebola exposure.

Director
Boston University
National Emerging Infectious Disease Lab


Professor
Boston University Chobanian & Avedisian School of Medicine
Virology, Immunology & Microbiology


Professor
Boston University College of Arts and Sciences
Biology






Title


Yr Title Project-Sub Proj Pubs
2021 Yeast Engineering Technology & Immunobiology Core 1ZIAAI005142-03
2021 mAbs and vaccines against SARS CoV-2 1ZIAAI005145-02
2021 Ebola Vaccine Immune Correlates and Mechanism of Protection 1ZIAAI005082-17
2021 mAbs and vaccines against Lassa Fever Virus 1ZIAAI005146-02
2021 Ebola Antibodies and Virology 1ZIAAI005081-17
2021 Marburg Vaccine Development 1ZIAAI005080-17
2021 Ebola Vaccine Development 1ZIAAI005079-17
2019 Ebola Vaccine Immune Correlates and Mechanism of Protection 1ZIAAI005082-15 14
2019 Ebola Virology 1ZIAAI005081-15 13
2019 Ebola Vaccine Development 1ZIAAI005079-15 15
Showing 10 of 66 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Hamer MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, Lee C, Preston A, Augustine B, Andrews C, Yamshchikov GV, Hickman S, Schech S, Hutter JN, Scott PT, Waterman PE, Amare MF, Kioko V, Storme C, Modjarrad K, McCauley MD, Robb ML, Gaudinski MR, Gordon IJ, Holman LA, Widge AT, Strom L, Happe M, Cox JH, Vazquez S, Stanley DA, Murray T, Dulan CNM, Hunegnaw R, Narpala SR, Swanson PA, Basappa M, Thillainathan J, Padilla M, Flach B, O'Connell S, Trofymenko O, Morgan P, Coates EE, Gall JG, McDermott AB, Koup RA, Mascola JR, Ploquin A, Sullivan NJ, Ake JA, Ledgerwood JE. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet. 2023 Jan 28; 401(10373):294-302. PMID: 36709074; DOI: 10.1016/S0140-6736(22)02400-X;
     
  2. Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL, Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023 Mar; 75(3):333-348. PMID: 36597810
     
  3. Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL, Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 Mar; 75(3):449-464. PMID: 36597813
     
  4. Lima NS, Musayev M, Johnston TS, Wagner DA, Henry AR, Wang L, Yang ES, Zhang Y, Birungi K, Black WP, O'Dell S, Schmidt SD, Moon D, Lorang CG, Zhao B, Chen M, Boswell KL, Roberts-Torres J, Davis RL, Peyton L, Narpala SR, O'Connell S, Serebryannyy L, Wang J, Schrager A, Talana CA, Shimberg G, Leung K, Shi W, Khashab R, Biber A, Zilberman T, Rhein J, Vetter S, Ahmed A, Novik L, Widge A, Gordon I, Guech M, Teng IT, Phung E, Ruckwardt TJ, Pegu A, Misasi J, Doria-Rose NA, Gaudinski M, Koup RA, Kwong PD, McDermott AB, Amit S, Schacker TW, Levy I, Mascola JR, Sullivan NJ, Schramm CA, Douek DC. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. Nat Commun. 2022 Dec 14; 13(1):7733. PMID: 36517467; PMCID: PMC9748393; DOI: 10.1038/s41467-022-35456-2;
     
  5. Hunegnaw R, Honko AN, Wang L, Carr D, Murray T, Shi W, Nguyen L, Storm N, Dulan CNM, Foulds KE, Agans KN, Cross RW, Geisbert JB, Cheng C, Ploquin A, Stanley DA, Geisbert TW, Nabel GJ, Sullivan NJ. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci Transl Med. 2022 Dec 14; 14(675):eabq6364.View Related Profiles. PMID: 36516269; DOI: 10.1126/scitranslmed.abq6364;
     
  6. Misasi J, Wei RR, Wang L, Pegu A, Wei CJ, Oloniniyi OK, Zhou T, Moliva JI, Zhao B, Choe M, Yang ES, Zhang Y, Boruszczak M, Chen M, Leung K, Li J, Yang ZY, Andersen H, Carlton K, Godbole S, Harris DR, Henry AR, Ivleva VB, Lei P, Liu C, Longobardi L, Merriam JS, Nase D, Olia AS, Pessaint L, Porto M, Shi W, Wolff JJ, Douek DC, Suthar MS, Gall J, Koup RA, Kwong PD, Mascola JR, Nabel GJ, Sullivan NJ. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization. bioRxiv. 2022 Nov 21. PMID: 35982683; PMCID: PMC9387125; DOI: 10.1101/2022.07.29.502029;
     
  7. Finch CL, King TH, Alfson KJ, Albanese KA, Smith JNP, Smock P, Jakubik J, Goez-Gazi Y, Gazi M, Dutton JW, Clemmons EA, Mattix ME, Carrion R, Rudge T, Ridenour A, Woodin SF, Hunegnaw R, Sullivan NJ, Xu R. Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs. Vaccines (Basel). 2022 Nov 15; 10(11). PMID: 36423030; PMCID: PMC9694189; DOI: 10.3390/vaccines10111935;
     
  8. Cross RW, Longini IM, Becker S, Bok K, Boucher D, Carroll MW, Díaz JV, Dowling WE, Draghia-Akli R, Duworko JT, Dye JM, Egan MA, Fast P, Finan A, Finch C, Fleming TR, Fusco J, Geisbert TW, Griffiths A, Günther S, Hensley LE, Honko A, Hunegnaw R, Jakubik J, Ledgerwood J, Luhn K, Matassov D, Meshulam J, Nelson EV, Parks CL, Rustomjee R, Safronetz D, Schwartz LM, Smith D, Smock P, Sow Y, Spiropoulou CF, Sullivan NJ, Warfield KL, Wolfe D, Woolsey C, Zahn R, Henao-Restrepo AM, Muñoz-Fontela C, Marzi A. An introduction to the Marburg virus vaccine consortium, MARVAC. PLoS Pathog. 2022 Oct; 18(10):e1010805.View Related Profiles. PMID: 36227853; PMCID: PMC9560149; DOI: 10.1371/journal.ppat.1010805;
     
  9. Finch CL, Dowling WE, King TH, Martinez C, Nguyen BV, Roozendaal R, Rustomjee R, Skiadopoulos MH, Vert-Wong E, Yellowlees A, Sullivan NJ. Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines (Basel). 2022 Aug 25; 10(9). PMID: 36146462; PMCID: PMC9503666; DOI: 10.3390/vaccines10091384;
     
  10. Tiemessen MM, Solforosi L, Dekking L, Czapska-Casey D, Serroyen J, Sullivan NJ, Volkmann A, Pau MG, Callendret B, Schuitemaker H, Luhn K, Zahn R, Roozendaal R. Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. Vaccines (Basel). 2022 Aug 05; 10(8). PMID: 36016151; PMCID: PMC9412258; DOI: 10.3390/vaccines10081263;
     
Showing 10 of 143 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 143 publications over 31 distinct years, with a maximum of 24 publications in 2021

YearPublications
19841
19871
19921
19934
19941
19952
19963
19973
19982
20003
20012
20032
20041
20053
20063
20074
20092
20104
20114
20123
20133
20149
20158
20163
20175
20188
20195
20207
202124
202219
20233

2022 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2021 National Institutes of Health: NIH Director’s Award
2020 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission,
2020 National Institutes of Health,: Special Act Award
2020 Service to America Medals: People’s Choice Award (Finalist)
2019 National Institute of Allergy and Infectious Diseases: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
2019 Science Magazine: Breakthrough of the Year (top ten nominated)
2018 National Institute of Allergy and Infectious Diseases, Vaccine Research Center: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
2018 Office of Technology Transfer, National Institutes of Health: Philip S. Chen Distinguished Lecture on Innovation and Technology Transfer
2017 Merrimack College: Honorary Doctorate
2016 Federal Laboratory Consortium for Technology Transfer (FLC): Excellence in Technology Transfer Award
2015 National Institutes of Health: NIH Director’s Award
2015 Politico Magazine: The Politico Top 50
2014 TIME: Time Person of the Year: Ebola Fighters, Time Magazine, for Research on Ebola virus vaccines
2011 National Institute of Allergy and Infectious Diseases,: Merit Award for Outstanding Contributions & Efforts in the Support of the NIAID Mission
Contact for Mentoring:

620 Albany St
Boston MA 02118
Google Map


Sullivan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department